Mucosal healing as an index of colitis activity: Back to histological healing for future indices

Inflammatory Bowel Diseases

Volumn 16, Issue 9, 2010, Pages 1628-1630

  Korelitz, Burton I ^a  

^a LENOX HILL HOSPITAL   (United States)

Author keywords

Histological best index; Mucosal healing

Indexed keywords

CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; PREDNISONE; SALAZOSULFAPYRIDINE; SULFONAMIDE; TUMOR NECROSIS FACTOR INHIBITOR;

BIOPSY; BLOOD CELL COUNT; COLITIS; CROHN DISEASE; DISEASE COURSE; DRUG EFFICACY; HISTOLOGY; HUMAN; INFLAMMATION; INFLAMMATORY CELL; MACROPHAGE; NEUTROPHIL; PRIORITY JOURNAL; RECTUM BIOPSY; REMISSION; REVIEW; SIGMOIDOSCOPY; STOMACH MUCOSA; TREATMENT RESPONSE; ULCERATIVE COLITIS; WOUND HEALING;

ANTI-INFLAMMATORY AGENTS; COLITIS; HUMANS; INTESTINAL MUCOSA; WOUND HEALING;

EID: 77956274695     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21268     Document Type: Review

References (18)

1. Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut. 2007;56:453-455.
2. Rubin DT. Utilizing mucosal healing as a treatment goal in ulcerative colitis. Gastroenterol Hepatol. 2009;11:771-773.
3. Kane S, Lu F, Kornbluth A, et al. Controversies in mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2009;15:796-800.
4. Schitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis. 2009;15:1295-1301.
5. Pineton de Chambrun G, Peyrin-Biroulet L, Lemann M, et al. Clinical implications of mucosal healing for the management of IBD. Gastroenterol Hepatol. 2010;7:15-29.
6. Truelove SC, Richards WC. Biopsy results in ulcerative colitis. Br Med J. 1956;1:1315-1318.
7. Dick AP, Grayson MJ. Ulcerative colitis: a follow-up investigation with mucosal biopsy studies. Br Med J. 1961;1:160-165.
8. Matts SGF. The value of rectal biopsies in the diagnosis of ulcerative colitis. Q J Med. 1961;30:393-407.
9. Dick AP, Holt LP, Dalton ER. Persistence of mucosal abnormality in ulcerative colitis. Gut. 1966;7:355-360.
10. Morson BC. Rectal biopsy in inflammatory bowel disease. N Engl J Med. 1972;287:1337-1339.
11. Korelitz BI, Sommers SC. Differential diagnosis of ulcerative colitis and granulomatous colitis by sigmoidoscopy, rectal biopsy and cell counts of rectal mucosa. Am J Gastroenterol. 1974;61:460-469.
12. Korelitz BI, Sommers SC. Response to drug therapy in ulcerative colitis. Evaluation by rectal biopsy and histopathological changes. Am J Gastroenterol. 1976;64-365-370.
13. Riley SA, Mani V, Goodman MJ, et al. Microscopic activity in ulcerative colitis: what does it mean? Gut. 1991;32:174-178.
14. D'Haens, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multi-center trial. Gastroenterology. 1999;116:1029-1034.
15. Geboes K, Riddell R, Ost A, et al. A reproducible grading scale for histological assessment of inflammation in UC. Gut. 2000;47:404-409.
16. Korelitz BI, Zlatanic J, Smith MJ, et al. Significance of WBC differential when leukopenia is induced by 6MP for IBD. Gastroenterology. 1997;113:1810-1814.
17. Korelitz BI, Sommers S. Response to drug therapy in Crohn's disease: evaluation by rectal biopsy and mucosal cell counts. J Clin Gastroenterol. 1984;6:123-127. (Pubitemid 14127898)
18. Bitton A, Peppercorn MA, Antonioli DA, et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001;120:13-20. (Pubitemid 32061864)